目的: 研究盐酸普拉克索联合多巴丝肼对帕金森氏病的临床效果。方法: 选择2012年1月至2016年12月进行诊治的帕金森氏病患者160例,随机分为观察组与对照组,每组各80例。对照组患者应用多巴丝肼治疗,观察组患者应用盐酸普拉克索联合多巴丝肼治疗,比较两组患者治疗后的运动功能情况、治疗前后的帕金森氏病评分量表(unified Parkinson’s disease rating scale,UPDRS)评分,以及两组患者出现恶心、呕吐、开关现象、精神症状等不良反应发生率。结果: 观察组患者的有效率为95.00 %,高于对照组的83.75 %(P＜0.05);两组患者治疗后的UPDRS评分均降低(P＜0.05),且观察组患者治疗后UPDRS评分低于对照组(P＜0.05);两组患者出现恶心、呕吐、开关现象、精神症状等不良反应发生率相比,差异无统计学意义(P＞0.05)。结论: 盐酸普拉克索联合多巴丝肼对帕金森氏病安全有效,能改善患者的运动功能,值得应用推广。

Objective: To study the clinical effect of pramipexole hydrochloride combined with benserazide hydrochloride on Parkinson disease.Methods: 160 cases of patients with Parkinson disease treated in the hospital from January 2012 to December 2016 were randomly divided into observation group and control group (n=80). The control group was treated with benserazide hydrochloride. The observation group was treated with pramipexole hydrochloride combined with benserazide hydrochloride. The motor function, the UPDRS score before and after treatment, and the incidence of adverse reactions such as nausea, vomiting, switching, psychiatric symptoms and so on were compared between the two groups.Results: The effective rate in the observation group was 95.00 %, which was significantly higher than that in the control group (83.75 %) (P＜0.05). The UPDRS scores of the two groups significantly decreased (P＜0.05) and the scores in the observation group was significantly lower than those in the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions such as nausea, vomiting, switching phenomenon and psychiatric symptoms in the two groups (P＞0.05).Conclusion: Pramipexole hydrochloride combined with benserazide hydrochloride is safe and effective in the treatment of Parkinson disease, which can significantly improve the motor function of patients. It is worthy of promotion.